JAN 1 9 2000 gg

Substitute for form 1449A/PTO

Sheet 1

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 3

Complete if Known			
Application Number 2	10/540,852		
Filing Date	June 27, 2005		
First Named Inventor	Kenji OKAJIMA		
Group Art Unit			
Examiner Name			
Attorney Docket Number	OKAJIMA		

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
50	AA	US-4,775,624	10-04-1988	Bang et al				
I	AB	US-5,147,638	09-15-1992	Esmon et al				
		us-						
		us-						
		us-						
		US-		×				

ı	FOREIGN PATENT DOCUMENTS							
	Examiner Initials*	Cite No.1	Foreign Patent Number Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>it known</i> )	Publication Date MM-DD-YYYY	of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6	
٦	A	AC	JP 61-205487	09-11-1986	Eli Lilly and Company			
Н	T	AD	EP 0 266 190 A2	05-04-1988	ZymoGenetics Inc.			
Ч		AE	JP 64-85084	03-30-1989	ZymoGenetics Inc.			
		AF	WO 95/34319 A1	12-21-1995	Genentech, Inc.			
Ц	1	AG	JP 10-501813	02-17-1998	Genentech, Inc.			
1								

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Cite		Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²				
GA		AOKI et al, "A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation", Int J Hematol 75(5):540-547 (2002)					
7		BAJZAR et al, "The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent", Blood 88(6):2093-2100 (1996)					
		BERNARD et al, "Efficacy and safety of recombinant human activated protein C for severe sepsis", N Engl J Med 344(10):699-709 (2001)					

Examiner Signature	1	That	Date Considered	11.28.06

<sup>\*</sup> EXAMINER: Initial if reterence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

JAN 1 3 700 B

titute for form 1449A/PTO

Sheet 2

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 3

Application Number	10/540,852	
Filing Date	June 27, 2005	
First Named Inventor	Kenji OKAJIMA	
Group Art Unit		
Examiner Name		
Attorney Docket Number	OKAJIMA1	

Complete if Known

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
M	AK	COMP et al, "Determination of functional levels of protein C, an antithrombotic protein, using thrombin-thrombomodulin complex", <u>Blood</u> 63(1):15-21 (1984)	
1	AL	GLASSMAN et al, "Thrombosis and coagulation abnormalities associated with cancer", Ann Clin Lab Sci 24(1):1-5 (1994)	
	AM	HALKIN et al, "Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis", Ann InternMed 96(5):561-565 (1982)	
	AN	IKEDA Y, "Atarashii Kokessen ' yaku Kakuroni > Kogyokoyaku (2) Kasseika Protein C", <u>Iyaku Journal</u> 35(4):1061-1066 (1999)	
	AO	JOYCE et al, "Disseminated Intravascular Coagulation in Severe Sepsis Patients Treated with Recombinant Human Activated Protein C, a Retrospective Subgroup Analysis from the PROWESS Trial", <u>Blood</u> 98(11):445a, 43 <sup>rd</sup> Annual Meeting Program Abstracts, #1866 (2001)	
	AP	KATSUURA Y, "Kokessen ' yaku no Genjo to Shin ' yaku Kaihatsu Kasseika Protein C no Kokessen Sayo", Folia Pharmacologica Japonica 116(5):290-297 (2000)	
	AQ	KINGSTON et al, "Peri-operative heparin: a possible adjuvant to surgery in colo-rectal cancer", Int J Colorect Dis 8(2):111-115 (1993)	
	AR	KISIEL et al, "Anticoagulant properties of bovine plasma protein C following activation by thrombin", <u>Biochemistry</u> 16(26):5824-5831 (1977)	
	AS	KISIEL W, "Human plasma protein C: isolation, characterization, and mechanism of activation by alpha-thrombin", <u>J Clin Invest</u> 64(3):761-769 (1979)	
	AT	KOHANNA et al, "Effect of perioperative low-dose heparin administration on the course of colon cancer", <u>Surgery</u> 93(3):433-438 (1983)	
	AU	LACAPRA et al, "The use of thrombus precursor protein, D-dimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism*, Blood Coagul Fibrinolysis 11(4):371-377 (2000)	
1	AV	LEBEAU et al, "Subcutaneous heparin treatment increases survival in small cell lung cancer", <u>Cancer</u> 74(1):38-45 (1994)	

Examiner Signature	Date Considered	21/28/06
--------------------	--------------------	----------

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

JAN 1 3 2006 W

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	(000 00	 	11000000
Sheet	3		1 3

Complete if Known				
Application Number	10/540,852			
Filing Date	June 27, 2005			
First Named Inventor	Kenji OKAJIMA	· · · · · · · · · · · · · · · · · · ·		
Group Art Unit				
Examiner Name				
Attomey Docket Number	OKAJIMA1			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
D	AW	LORETO et al, "Coagulation and cancer: implications for diagnosis and management", Patho Oncol Res 6(4):301-312 (2000)	
	AX	MITATE et al, "Kessensho no Rinsho-Ekigaku to Byotai DIC-Byotai no Tayosei", Medicina 37(5):735-737 (2000)	
	AY	MURAKAMI et al, "Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production", Am J Physiol 272(2 Pt 1):L197-L202 (1997)	
	AZ	REZAIE A, "Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C", <u>J Biol Chem</u> 276(19):15567-15570 (2001)	
	ВА	SAKATA et al, "Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity", Proc Natl Acad Sci USA 82(4):1121-1125 (1985)	
	ВВ	SCATES S, "Diagnosis and treatment of cancer-related thrombosis", <u>Semin Thromb Hemost</u> 18(4):373-379 (1992)	
	ВС	SUTHERLAND et al, "Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment", Am J Hematol 72(1):43-52 (2003)	
	BD	SUZUKI et al, "Inactivation of human coagulation factor V by activated protein C", <u>J Biol Chem</u> 258(3):1914-1920 (1983)	
	BE	TAYLOR et al, "Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon", <u>J Clin Invest</u> 79(3):918-925 (1987)	
	BF	ZACHARSKI L, "Basis for selection of anticoagulant drugs for therapeutic trials in human malignancy", Haemostasis 16:(3-4):300-320 (1986)	
	BG	ZACHARSKI L, "Heparin and cancer", Thromb Haemost 80(1):10-23 (1998)	
	ВН	The Welfare Ministry, Research team for specified diseases, coagulopathy, Report in 1987 p.37-41 (1988)	

Examiner Signature	I Mide	Date Considered	11.28.06
- 3			

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.